Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Accumulated Expenses (2016 - 2017)

Historic Other Accumulated Expenses for Agios Pharmaceuticals (AGIO) over the last 6 years, with Q1 2017 value amounting to $1.3 million.

  • Agios Pharmaceuticals' Other Accumulated Expenses rose 38684.21% to $1.3 million in Q1 2017 from the same period last year, while for Mar 2017 it was $1.3 million, marking a year-over-year increase of 38684.21%. This contributed to the annual value of $168000.0 for FY2016, which is 8721.46% down from last year.
  • Agios Pharmaceuticals' Other Accumulated Expenses amounted to $1.3 million in Q1 2017, which was up 38684.21% from $168000.0 recorded in Q4 2016.
  • Agios Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $1.3 million for Q4 2015, and its period low was $93000.0 during Q2 2014.
  • Over the past 5 years, Agios Pharmaceuticals' median Other Accumulated Expenses value was $434000.0 (recorded in 2013), while the average stood at $544500.0.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Other Accumulated Expenses surged by 70860.22% in 2015, and later crashed by 8721.46% in 2016.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Other Accumulated Expenses stood at $140000.0 in 2013, then skyrocketed by 215.71% to $442000.0 in 2014, then surged by 197.29% to $1.3 million in 2015, then tumbled by 87.21% to $168000.0 in 2016, then soared by 670.83% to $1.3 million in 2017.
  • Its Other Accumulated Expenses stands at $1.3 million for Q1 2017, versus $168000.0 for Q4 2016 and $538000.0 for Q3 2016.